Adis unveils a bold new look for pharmacovigilance at DIA

Two members of the Adis Product Management team have recently returned from the DIA Annual Meeting in Philadelphia where they officially launched Adis Pharmacovigilance to 7,000+ attendees.

For more than a decade, Adis has provided regulatory literature monitoring services under the name of Reactions Pharmacovigilance Service. This range of customizable outsourcing solutions includes ICSR monitoring, local literature monitoring and annual reports. The service has now been re-launched with a new name – Adis Pharmacovigilance .

A champagne reception was held during the DIA meeting to celebrate the official launch and the event attracted many visitors to the Springer Nature stand. The conference itself presented many opportunities for the team to speak to attendees about their current pharmacovigilance set-up and needs.

James DeFalco, Executive Licensing Manager, speaking with delegates during the champagne reception. 
Suzanne Berresford, Product Manager for Adis Pharmacovigilance, at the Springer Nature stand.

Over the coming weeks the Adis team will be preparing for a further three pharmacovigilance-related conferences– World Drug Safety Europe in Munich, the 3rd Annual Risk Management & Pharmacovigilance Summitin Vienna, and the ISoP Annual Meeting which will take place in Agra, India.

Further information about Adis Pharmacovigilance is available on the landing pageadis.com/pharmacovigilance.

More than half a million users trust AdisInsight

Adis announced recently that its drug development database, AdisInsight, has been visited by more than half a million users since it launched in 2015.

AdisInsight delivers the most compelling, current evidence on drug treatments being developed worldwide – how well they work, how safe they are, who is working on them, and how soon they will be available.

The platform brings together expertly-written content on drugs, deals, trials and safety. This content was previously offered through three separate databases – R&D Insight, Clinical Trials Insight and Pharmacovigilance Insight, but the launch of AdisInsight  saw this content come together in one place for the first time.

 

editorial-review-grab
What makes AdisInsight different is our scientific expertise

 

“I have completed more than 100 evaluations using AdisInsight. It is absolutely critical that the information I include is proven and trustworthy and it has been so every time.”

Business Development & Licensing Manager, top 50 pharma

The statistics, provided by Google Analytics, are a strong endorsement of the customer-driven development approach adopted by the AdisInsight team, which sees the platform continuously evolving in response to customer feedback.

The largest proportion of users to date are based in the United States, followed by India, the United Kingdom, Japan and Germany. AdisInsight has subscribers across multiple industries including pharma and biotech; finance, business and banking; hospitals and healthcare; and academia.